

PARTICIPANT IDENTIFICATION#: [__][__][__][__]--- [__][__][__]

COVID-19 CORE CASE REPORT FORM

ACUTE RESPIRATORY INFECTION CLINICAL CHARACTERISATION DATA TOOL

DESIGN OF THIS CASE REPORT FORM (CRF)

This CRF is set up in modules to be used for recording data on the ISARIC COVID-19 Core Database or for independent studies.

Module 1 and Module 2 complete on the first day of presentation/admission or on first day of <u>COVID-19 assessment</u>. Module 2 also complete on first day of admission to ICU or high dependency unit, or if receiving critical care in any ward, and on any days that research specific samples are taken. In addition, complete daily if of interest for local, specific analysis. Continue to follow-up patients who transfer between wards.

Module 3 (Outcome) complete at discharge or death

GENERAL GUIDANCE

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected prospectively or retrospectively if the patient is enrolled after the admission date.
- For more detailed guidance on how to complete these forms, please refer to the CRF Completion Guideline
- Participant Identification Numbers consist of a 3 or 5 digit site code and a 4 digit participant number. You can obtain a site code and register on the data management system by contacting <u>ncov@isaric.org</u>. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporate alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page.
- Printed paper CRFs may be used for later transfer of the data onto the electronic database.
- For participants who return for re-admission to the same site, **start a new form with a different Participant Identification Number**. Please check "YES-admitted previously to this facility" in the RE-ADMISSION section. Enter as 2 separate entries in the electronic database.
- For participants who transfer between two sites that are both collecting data on this form, it is preferred to have
 the data entered by a single site as a single admission, under the same Participant Identification Number. When
 this is not possible, the first site should record "Transfer to other facility" as an OUTCOME, and the second site
 should start a new form with a new patient number and indicate "YES-transferred from other facility" READMISSION.
- Complete every line of every section, except where the instructions say to skip a section based on a response.
- Selections with circles (**○**) are single selection answers (choose one answer only). Selections with square boxes (□) are multiple selection answers (choose as many answers as are applicable).
- Mark 'Not done' for any results of laboratory values that are not available, not applicable or unknown.
- Avoid recording data outside of the dedicated areas. Sections are available for recording additional information.
- If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- Please transfer all paper CRF data to the electronic database. All paper CRFs needs to be stored locally, do not send any forms to us. Data are accepted only via secure electronic database.
- Please enter data on the electronic data capture system at https://ncov.medsci.ox.ac.uk/. If your site would like to collect data independently, we are happy to support the establishment of locally hosted databases.
- Please contact us at <u>ncov@isaric.org</u> if you need help with databases, if you have comments and to let us know that you are using the forms.



CLINICAL INCLUSION CRITERIA



Sex at Birth: OMale OFemale ONot specified/Unknown

Pregnant? OYES **O**NO **O**Unknown

MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM

(Suspected or confirmed novel coronavirus (COVID-19) infection: QYES QNO
(Is COVID-19 the reason for hospital admission?)
Yes, COVID-19 is the reason for hospital admission
No, the patient is admitted to hospital for a reason other than COVID-19
DEMOGRAPHICS
Clinical centre name: Country:
(Enrolment date /first COVID-19 assessment date: [_D_](_D_]/[_M_](_M_]/[_2_][_0_](_Y_](_Y_]
(Ethnic group (check all that apply): ☐Arab) ☐Black ☐East Asian ☐South Asian ☐West Asian ☐Latin American ☐White
□Aboriginal/First Nations □Other: Ounknown
(Employed as a Healthcare Worker? OYES) ONO OUnknown (Employed in a microbiology laboratory? OYES) ONO OUnknown

Age [___][___]years OR [___][___]months

MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM

ONSET & ADMISSION
Onset date of first/earliest symptom: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
Most recent presentation/admission date at this facility: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]

If YES: Gestational weeks assessment: [___][___] weeks

SIGNS AND SYMPTOMS AT HOSPITAL ADMISSION (first available data at presentation/admission – within 24 hours)

Temperature: [___][__].[__]O°C or O°F

[HR: [___][__]beats/minute]

Systolic BP: [__][__]mmHg

Diastolic BP: [__][__]mmHg

Oxygen saturation: [__][__]%

On: ORoom air OOxygen therapy

Ounknown

Sternal capillary refill time >2sec. OYES ONO OUnknown

Height: [__][__]cm

Weight: [__][__]kg

SIGNS AND SYMPTOMS ON ADMISSION (Unk = Unknown)					
(History of fever)	OYES ONO OUnk	(Fatigue / Malaise)	OYES ONO OUNK		
Cough OYES - non-productive	O YES - productive	Anorexia	OYES ONO OUNK		
•YES - with haemoptysis	O NO O Unk	(Altered consciousness/confusion)	OYES ONO OUNK		
(Sore throat)	OYES ONO OUNK	(Muscle aches (myalgia))	OYES ONO OUNK		
(Runny nose (rhinorrhoea)	OYES ONO OUNK	(Joint pain (arthralgia))	OYES ONO OUNK		





(Wheezing)	OYES ONO OUNK	(Inability to walk)	OYES ONO OUNK
(Shortness of breath	OYES ONO OUNK	(Abdominal pain)	OYES ONO OUNK
Lower chest wall indrawing	OYES ONO OUNK	Diarrhoea	OYES ONO OUNK
Chest pain	OYES ONO OUNK	Vomiting / Nausea	OYES ONO OUNK
Conjunctivitis	OYES ONO OUNK	(Skin rash)	OYES ONO OUNK
Lymphadenopathy	OYES ONO OUNK	(Bleeding (Haemorrhage)	OYES ONO OUNK
(Headache)	OYES ONO OUNK	If YES, specify site(s):	
(Loss of smell (Anosmia)	OYES ONO OUNK	Other symptom(s)	OYES ONO OUNK
Loss of taste (Ageusia)	OYES ONO OUNK	If YES, specify:	
(Seizures)	OYES ONO OUNK		

MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM

PRE-ADMISSION MEDICATION (taken within 14 days prior to admission/presentation at healthcare facility)					
Steroids	OYES ONO OUNK If YES, OOral OInhaled OUNK				
Other immunosuppressant agents (not oral steroids)	OYES ONO OUNK				
Antibiotics	OYES ONO OUnk If YES, agent(s):				
Antivirals	OYES ONO OUnk If YES, agent(s):				
Other targeted COVID-19 Medications	OYES ONO OUNK If YES, agent(s):				

CO-MORBIDITIES AND RISK FACTORS (existing prior to admission and ongoing)							
Chronic cardiac disease (not hypertension)	OYES ONO OUNK	Chronic hematologic disease	OYES ONO OUNK				
(Hyportonian)	OVES ONO OHAR	AIDS / HIV OYES-on ART OYES-not If YES, most recent CD4 count:	on ART) ONO OUnk				
(Hypertension)	OYES) ONO OUNK	O< 200 O200-< 500 O≥ 500 o	eells/uL) O Unk				
(Chronic pulmonary disease (not asthma)	OYES ONO OUNK	OYES-Type 1 OYES-Gestational (If YES, HbA1C results (within last 6 n Units: Ommol/mol Ommol/L	nonths):				
Asthma (physician diagnosed)	OYES ONO OUNK	(Rheumatologic disorder)	OYES ONO OUNK				
(Chronic kidney disease)	OYES ONO OUNK	Dementia	OYES ONO OUNK				
Obesity (as defined by clinical staff)	OYES ONO OUNK	(Tuberculosis)	OYES ONO OUNK				
Moderate or severe liver disease	OYES ONO OUNK	(Malnutrition)	OYES ONO OUNK				
Mild liver disease	OYES ONO OUnk	(Smoking) QYES) QNever smoked) QI	Former smoker) Q Unk				
Asplenia	OYES ONO OUNK	Other relevant risk factor(s)	OYES ONO OUNK				
Chronic neurological disorder	OYES ONO OUNK	(If YES, specify:)					
(Malignant neoplasm)	OYES ONO OUNK						





ISARIC

MODULE 2: CASE REPORT FORM ON ADMISSION, CRITICAL CARE, RESEARCH SAMPLING

Complete on the day of admission or first COVID-19 investigation, and on the first day of ICU admission (if different from day of admission). In addition, complete for days when biochemical results are available.

complete for days when biochemical results are available.
SIGNS AND SYMPTOMS (Record the worst value between 00:00 to 24:00 on day of assessment)(worst=furthest from normal range)
DATE OF ASSESSMENT (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
(Highest temperature: [][].[] O°C or O°F HR: [][]beats/minute RR: [][]breaths/minute
Systolic BP: [][]mmHg Diastolic BP: [][]mmHg
Oxygen saturation SaO ₂ [][]%
Any supplemental oxygen: OYES ONO OUnknown If yes,
(FiO ₂ (0.21-1.0) []. [] or [] % or [][] L/min (Highest L/min)
PaO ₂ (at time nearest to the FiO ₂ recorded at top of page) [][]OkPa or OmmHg ONot done
PaO₂ sample type: OArterial OCapillary OVenous OUnknown
From same blood gas record as PaO ₂ :
PCO ₂ OkPa or OmmHg pH HCO ₃ - mEq/L Base excess mmol/L
Sternal capillary refill time >2seconds OYES ONO OUnknown
AVPU: Alert [] Verbal[] Pain [] Unresponsive [] Glasgow Coma Score (GCS / 15) [][]
(Richmond Agitation-Sedation Scale (RASS) []
Mean Arterial Blood Pressure [][]mmHg OUnknown
(Urine flow rate [][][]mL/24 hours)
Is the patient currently receiving, or has received (between 00:00 to 24:00 on day of assessment)
Current admission to ICU/ITU/IMC/HDU? OYES ONO OUnknown
(High-flow nasal cannula oxygen therapy?) OYES ONO OUnknown
Non-invasive ventilation (Any)? OYES ONO OUNKnown If YES: OBIPAP OCPAP OUNKnown
Non-invasive ventilation (Any)? OYES ONO OUNknown If YES: OBIPAP OCPAP OOther OUNknown Invasive ventilation? OYES ONO OUNknown
Invasive ventilation? OYES ONO OUnknown
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown If yes, Oduring invasive ventilation Owhilst self-ventilating Ounknown
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown(If yes, Oduring invasive ventilation Owhilst self-ventilating OUnknown Inhaled Nitric Oxide? OYES ONO OUnknown
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown(If yes, Oduring invasive ventilation Owhilst self-ventilating OUnknown Inhaled Nitric Oxide? OYES ONO OUnknown Tracheostomy inserted? OYES ONO OUnknown
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown(If yes, Oduring invasive ventilation Owhilst self-ventilating OUnknown Inhaled Nitric Oxide? OYES ONO OUnknown Tracheostomy inserted? OYES ONO OUnknown Extra corporeal life support (ECLS/ ECMO)? OYES ONO OUnknown If YES: OVV OAV OCENTRAL OUNKnown
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown(If yes, Oduring invasive ventilation Owhilst self-ventilating OUnknown Inhaled Nitric Oxide? OYES ONO OUnknown Tracheostomy inserted? OYES ONO OUnknown Extra corporeal life support (ECLS/ ECMO)? OYES ONO OUnknown Renal replacement therapy (RRT) or dialysis? OYES ONO OUnknown
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown (If yes, Oduring invasive ventilation Owhilst self-ventilating OUnknown Inhaled Nitric Oxide? OYES ONO OUnknown Tracheostomy inserted? OYES ONO OUnknown Extra corporeal life support (ECLS/ ECMO)? OYES ONO OUnknown (If YES: OVV OAV OCentral OUnknown Renal replacement therapy (RRT) or dialysis? OYES ONO OUnknown Any vasopressor/inotropic support? OYES ONO OUnknown (If NO, select NO for the next 3 questions)
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown If yes, Oduring invasive ventilation Owhilst self-ventilating OUnknown Inhaled Nitric Oxide? OYES ONO OUnknown Tracheostomy inserted? OYES ONO OUnknown Extra corporeal life support (ECLS/ ECMO)? OYES ONO OUnknown If YES: OVV OAV OCentral OUnknown Renal replacement therapy (RRT) or dialysis? OYES ONO OUnknown Any vasopressor/inotropic support? OYES ONO OUnknown (if NO, select NO for the next 3 questions) Dopamine <5μg/kg/min OR Dobutamine OR milrinone OR levosimendan:
Invasive ventilation? OYES ONO OUnknown Prone positioning? OYES ONO OUnknown If yes, Oduring invasive ventilation Owhilst self-ventilating OUnknown Inhaled Nitric Oxide? OYES ONO OUnknown Tracheostomy inserted? OYES ONO OUnknown Extra corporeal life support (ECLS/ ECMO)? OYES ONO OUnknown (If YES: OVV OAV OCentral OUnknown) Renal replacement therapy (RRT) or dialysis? OYES ONO OUnknown Any vasopressor/inotropic support? OYES ONO OUnknown (If NO, select NO for the next 3 questions) Dopamine <5μg/kg/min OR Dobutamine OR milrinone OR levosimendan: OYES ONO Dopamine 5-15μg/kg/min OR Epinephrine/Norepinephrine < 0.1μg/kg/min OR vasopressin OR phenylephrine: OYES ONO





MODULE 2: CASE REPORT FORM ON ADMISSION, CRITICAL CARE, RESEARCH SAMPLING

Complete on the day of admission or first COVID-19 investigation, and on the first day of ICU admission (if different from day of admission). In addition, complete for days when biochemical results are available.

LABORATORY RESULTS (on	admission, on any admissi	on to ICU, t	hen daily) – complete ever	y line	
DATE OF ASSESSMENT (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]					
LABORATORY RESULTS (*re	ecord units if different fro	om those li	sted)		
Record the worst value between	en 00:00 to 24:00 on day o	f assessmer	nt (if Not Available write 'N/	A')	
Parameter	Value*	Not done	Parameter	Value*	Not done
Haemoglobin (g/L)		0	Urea (BUN) (mmol/L)		0
WBC count (x10 ⁹ /L)		0	Lactate (mmol/L)		0
Lymphocyte count (10 ⁹ /L)		0	Creatinine (µmol/L)		0
Neutrophil count (10 ⁹ /L)		0	Sodium (mmol/L)		0
Haematocrit (%)		0	Potassium (mmol/L)		0
Platelets (x10 ⁹ /L)		0	Procalcitonin (ng/mL)		0
APTT (seconds))		0	CRP (mg/L)		0
APTR		0	LDH (U/L)		0
PT (seconds)		0	Creatine kinase (U/L)		0
INR		0	Troponin I (ng/mL)		0
ALT/SGPT (U/L)		0	D-dimer (mg/L)		0
Total bilirubin (µmol/L)		0	Ferritin (ng/mL)		0
AST/SGOT (U/L)		0	(IL-6 (pg/mL)		0
Glucose (mmol/L)		0	Fibrinogen (mg/dl)		0

TREATMENT: At ANY time during hospitalisation, did the patient receive/undergo:							
Any Oxygen therapy? OYES ONO OUnknown If YES, total duration:days Ounknown							
Maximum O ₂ flow volume: O <2 L/min O2-5 L/min O6-10 L/min O11-15 L/min O>15 L/min							
Non-invasive ventilation? (Any)	OYES ONO O	Unknown	If YES, total duration:	days O Unknown			
Invasive ventilation? (Any)	OYES ONO O	Unknown	If YES, total duration:	days OUnknown			
High flow nasal oxygen	OYES ONO OU	<u>Jnknown</u>	If YES, total duration:	days Q Unknown			
Prone Positioning?	OYES ONO O	Unknown					
Inhaled Nitric Oxide?	OYES ONO O	Unknown					
Tracheostomy inserted?	OYES ONO O	Unknown					
Extracorporeal support (ECMO)?	OYES ONO O	Unknown	If YES, total duration:	days OUnknown			
Renal replacement therapy (RRT) or dialysis? OYES ONO OUNknown							
Inotropes/vasopressors?	OYES ONO OU	Unknown					
ICU or High Dependency Unit admission? OYES ONO OUnknown If YES, total duration:days Ounknown							
If YES, date of ICU admission:							
date of ICU discharge: [D][D]/[M][M]/[2][0][Y][Y] OUnknown							





COMPLICATIONS: At any time during hospitalisation did the patient experience: (Unk = Unknown)					
Viral pneumonia/pneumonitis	OYES ONO OUNK	Meningitis / Encephalitis	OYES ONO OUNK		
Bacterial pneumonia	OYES ONO OUNK	Bacteremia	OYES ONO OUNK		
Acute Respiratory Distress Syndrome	OYES ONO OUNK	Coagulation disorder / DIC	OYES ONO OUNK		
Pneumothorax	OYES ONO OUNK	Pulmonary Embolism	OYES ONO OUNK		
Pleural effusion	OYES ONO OUNK	Deep Vein Thrombosis	OYES ONO OUNK		
Cryptogenic organizing pneumonia (COP)	OYES ONO OUNK	Other thromboembolism (not PE or DVT)	OYES ONO OUNK		
Bronchiolitis	OYES ONO OUNK	Anemia	OYES ONO OUNK		
Cardiac arrest	OYES ONO OUNK	Rhabdomyolysis / Myositis	OYES ONO OUNK		
Myocardial infarction	OYES ONO OUNK	Acute renal injury/ Acute renal failure	OYES ONO OUNK		
Cardiac ischaemia	OYES ONO OUNK	Gastrointestinal haemorrhage	OYES ONO OUNK		
Cardiac arrhythmia	OYES ONO OUNK	Pancreatitis	OYES ONO OUNK		
Myocarditis / Pericarditis	OYES ONO OUNK	Liver dysfunction	OYES ONO OUNK		
Endocarditis	OYES ONO OUNK	Hyperglycemia	OYES ONO OUNK		
Cardiomyopathy	OYES ONO OUNK	Hypoglycemia	OYES ONO OUNK		
Congestive heart failure	OYES ONO OUNK	Other	OYES ONO OUNK		
Seizure	OYES ONO OUNK	(If YES, specify:			
Stroke / Cerebrovascular accident	OYES ONO OUNK				

DIAGNOSTICS					
Section 1: RESPIRATORY VIRUS PCR TESTING					
SARS-CoV-2 (COVID-19): O Positive O Not done O Unknown					
Was other pathogen testing done during this illness episode? OYES (complete section) ONO OUnknown					
Influenza: OPositive ONegative ONot done OUnknown					
If Positive: OA-not typed OA/H3N2 OA/H1N1pdm09 OA/H7N9 OA/H5N1 OB OOther:OUnk					
Respiratory Syncytial Virus (RSV): OPositive ONegative ONot done OUnknown					
Adenovirus: OPositive ONegative ONot done OUnknown					
Section 2: BACTERIAL TESTING					
Bacteria: OPositive ONegative ONot done (If Positive, specify:					
Other pathogen/s detected: OYES ONO OUnknown (If YES, specify all:OUnknown)					
Section 3: RADIOLOGY					
Clinical pneumonia diagnosed? OYES ONO OUnknown					
Chest X-Ray performed? OYES ONO OUnknown If Yes: Were infiltrates present? OYES ONO OUnknown					
CT performed? OYES ONO OUnknown (If Yes: Were infiltrates present? OYES ONO OUnknown)					





DIAGNOSTICS continued						
Section 4: PATHOGEN TESTING DETAILS						
(DD/MM/YYYY)	(Biospecimen Type)	Laboratory test Method	(Result)	(Pathogen) (Tested/Detected)		
D D / M M /20 Y Y	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFECES/rectal swab OOther, Specify:	OPCR OCulture Other, Specify:	OPositive ONegative OUnknown			
D D/M M/20 Y Y	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFeces/rectal swab OOther, Specify:	OPCR OCulture OOther, Specify:	OPositive ONegative OUnknown			
_D_D/M_M/20_Y_Y	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFECES/rectal swab OOther, Specify:	OPCR OCulture Other, Specify:	OPositive ONegative OUnknown			
D D / M M /20 Y Y	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFaeces/rectal swab OOther, Specify:	OPCR OCulture OOther, Specify:	OPositive ONegative OUnknown			

MEDICATION: While hospitalised or at discharge, were any of the following administered? (Unk=Unknown)					
ANTIVIRAL OR COVID-19 TARGETED AGENT? OYES ONO OUNknown If YES, specify (all):					
□ Ribavirin Date commenced[D][D]/[M][M]/[2][0][Y][Y] ◆ OUnk	Duration : days	OUnk			
□ Lopinavir/Ritonavir Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUnk	Duration : days	OUnk			
□ Remdesivir (Veklury) Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUnk	Duration : days	OUnk			
☐ Interferon alpha Date commenced [D][D]/[M][M]/[2_][0_][Y][Y] OUnk	Duration : days	O Unk			
☐ Interferon beta Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUnk	Duration : days	OUnk			
☐ Chloroquine/hydroxychloroquine:					
Date commenced _D_/(_M_](_M_)/(_2_](_0_](_Y_](_Y_]	Duration :days	OUnk			
☐ Interleukin-6 (IL-6) inhibitor (IF YES which: ☐ Tocilizumab ☐ Sarilumab ☐ Other IL-6 inhibitor		_ O Unk			
Date commenced [D][D]/[M][M]/[2][0][Y][Y] ⊙ Unk	Duration :days	OUnk			
☐ Convalescent plasma Date commenced [D][D]/[M][M]/[2][0][Y][Y] Ounk	Duration :days	OUnk			
☐ Anti-influenza anti-viral (IF YES which: ☐Oseltamivir (Tamiflu®) ☐ Zanamivir OUnk					
Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUnk	Duration :days	OUnk			
□ Other Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] O Unk					
duration:days) • Unk					






MEDICATION (continued):				
ANTIBIOTIC? OYES ONO Ounknown If yes, specify all:				
Agent 1: Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_](Duration:days)				
Agent 2: Date commenced D D D D D D D D D D D D D D D D D D D				
Agent 3: Date commenced [D][D]/[M][M]/[2][0][Y][Y] Duration: days Ounk				
CORTICOSTEROID? OYES ONO OUNknown				
If YES: Dexamethasone? OYES ONO OUnknown				
If YES, check all that apply:				
☐ 6mg once per day (od)? OYES ONO OUnknown If YES, Route: ☐ Oral ☐ Intravenous OUnk				
If YES, Date commenced [D][D]/[M][M]/[2][0][Y][Y] Duration: days				
☐ other dose or frequency? OYES ONO OUnknown If YES, Route: ☐ Oral ☐ Intravenous OUnk				
If YES, Date commenced [D][D]/[M][M]/[2][0][Y][Y]Duration: days				
If YES: Other corticosteroid? OYES ONO OUNknown				
If YES: Which steroid: ☐ Prednisolone ☐ Hydrocortisone ☐ Methylprednisolone ☐ Other				
Route: Oral Intravenous Ounk				
ANTICOAGULATION? OYES ONO OUNK				
(If YES: Agent:				
Route: Subcutaneous Intravenous (IV) Ounk				
(Indication: ☐ therapeutic (treatment of DVT/PE) ☐ enhanced prophylaxis for COVID-19 ☐ routine inpatient prophylaxis ☐ Unk				
ANTIFUNGAL AGENT? OYES ONO OUNK				
OTHER treatments administered for COVID-19 including experimental or compassionate use? OYES ONO OUNK				
If YES, specify agent and timing of administration:				
Agent 1:				
Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUnk Duration: days				
Agent 2:				
Agent 2: Date commenced [D][D]/[M][M]/[2][0][Y][Y] QUnk Duration: days QUnk				
Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUNK Duration: days				
Date commenced [D][D]/[M][M]/[2][0][Y][Y] Ounk Duration: days Ounk Agent 3:				
Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUNK Duration: days				











PARTICIPANT IDENTIFICATION #: [__][__][__][__]--- [__][__][__]

POST PARTUM (within 6 weeks of delivery)? OYES ONO OUnknown (if NO or Unknown skip this section)				
Pregnancy Outcome: OLive birth OStill birth Delivery date: D Delivery date				
Baby tested for COVID-19/SARS-CoV-2 infection? OYES ONO OUnknown				
If YES, result of test: O Positive O Negative O Unknown (If Positive, complete a separate CRF for baby)				
INFANT – Less than 1 year old? OYES ONO (If NO skip this section)				
Birth weight: []Ckg or Olbs OUnknown				
Gestational outcome: O Term birth (≥37wk GA) OPreterm birth (<37wk GA) OUnknown				
Breastfed? OYES-currently breastfeeding OYES-breastfeeding discontinued ONO OUnknown				
Vaccinations appropriate for age/country? OYES ONO OUnknown				
PREVIOUS COVID-19 INFECTIONS				
Has the patient had COVID-19 previously? O No O Yes - once previously O Yes - twice previously O Yes - three times previously (there is more space on the eCRF to capture this)				
First COVID-19 infection: When did their first COVID infection occur? (MM/YYY)				
Was their first COVID infection confirmed by testing: OYes, confirmed by testing ONo, not confirmed by testing				
Were they admitted to hospital for their first infection of COVID? OYes ONo				
Second COVID-19 infection: When did their second COVID infection occur? (MM/YYY)				
Was their second COVID infection confirmed by testing: OYes, confirmed by testing ONo, not confirmed by testing				
Were they admitted to hospital for their second infection of COVID? OYes ONO				
If data on this patient was previously recorded in this study, record the Participant Identification Number (PIN) previously used in the section below				
RE-ADMISSION AND PREVIOUS PIN				
Was the patient admitted previously or transferred from any other facility during this illness episode?				
OYES-admitted previously to this facility OYES—transferred from other facility ONO OUnknown				
Number of previous admissions for this infection:				
Has this patient's data been previously collected under a different patient number? OYES ONO OUnknown				
If YES, Participant Identification number (PIN):				
VACCINATIONS				
Covid-19 vaccination: OYES ONO OUNK				
Date of first vaccine: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_] Date: Oactual Oestimated				
Type of first vaccine: OPfizer/BioNTech OAstraZeneca Oxford (Covishield in India) OModerna ONovavax OJanssens (Johnson & Johnson) OSinopharm OSinovac OSputnik V OCovaxin OCanSinoBIO OUnknown Oother, please specify				
Date of second vaccine: D] D]/ M] M]/ Q] Date: Oactual Oestimated				
Type of second vaccine: OPfizer/BioNTech OAstraZeneca/University of Oxford (Covishield in India) OModerna ONovavax OJanssens (Johnson & Johnson) OSinopharm OSinovac OSputnik V OCovaxin OCanSinoBIO OUnknown Oother, please specify				
Date of third vaccine : D D M M C2 O Y Y Date: Oactual Oestimated				
Type of third vaccine: OPfizer/BioNTech OAstraZeneca/University of Oxford (Covishield in India) OModerna ONovavax OJanssens (Johnson & Johnson) OSinopharm OSinovac OSputnik V OCovaxin OCanSinoBIO OUnknown Oother, please specify				





Organization	ISARIC	

Influenza vaccination within the last 6 months: OYES ONO OUNknown

Date of influenza vaccine: [D][D]/[M][M]/[2][0][Y][Y] Date: Oactual Oestimated

Was patient diagnosed with Covid-19? OYES ONO OUnknown

If yes, was the diagnosis based on: Olaboratory confirmation O clinical assessment

Is the patient infected with a variant of concern (VOC)?

O Unknown

O No: Variant is known and no VOC identified

O Yes: Delta - B.1.617.2, identified Oct 2020

O Yes: Omicron, B.1.1.529, identified Nov 2021

O Yes: Alpha - B.1.1.7, identified in UK Sept 2020

O Yes: Beta - B.1.351, identified in South Africa May 2020

O Yes: Gamma - P.1, identified in Brazil Nov 2020

O Yes: Epsilon - B.1.427/B.1.429, identified in USA Mar 2021

O Yes: Zeta - P.2, identified in Brazil Apr 2020

O Yes: Eta - B.1.525, identified in Multiple Countries Dec 2020

O Yes: Theta - P.3, identified in Philippines Jan 2021

O Yes: Iota - B.1.526, identified in USA Nov 2020

O Yes: Kappa - B.1.617.1, identified in India Oct 2020

O Yes: Lambda - C.37, identified in Peru Dec 2020

O Yes: Mu - B.1.621, identified in Colombia Jan 2021

O Yes: A variant not listed above

Please check the REDCAP database for variants not listed above. New variants will be added to the database as they are identified.

If the Omicron variant was identified, what method was used to identify it?

OGenomic sequencing OS-gene target failure (SGTF) testing OPCR genotyping OUnknown or untested